Plasma protein binding

New EO Care Survey of 1000+ Finds 18 Percent of Americans Use Cannabis for Health Reasons Today, but 65 Percent Would Use If Guided by a Clinician

Retrieved on: 
Tuesday, October 24, 2023

All respondents were employed at least part-time and were from US states where cannabis is legal for medical and/or recreational use.

Key Points: 
  • All respondents were employed at least part-time and were from US states where cannabis is legal for medical and/or recreational use.
  • 18 percent of respondents have used cannabis for health reasons in the past year, 19 percent have used cannabis for recreational reasons, and 14 percent have used it for both.
  • 51 percent said they would be likely/very likely to use cannabis if it were offered by their health plan.
  • 65 percent of respondents said they would feel more comfortable using cannabis if it were screened and dosed by a clinician.

Europe Pharmaceutical Packaging & Labeling (Primary, Secondary, Tertiary) Market Insights Report 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023

The "Europe Pharmaceutical Packaging & Labeling Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Pharmaceutical Packaging & Labeling Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • This report offers market size & forecast data for the pharmaceutical packaging & labeling market in Europe.
  • This report provides a comprehensive and current market scenario of the Europe pharmaceutical packaging & labeling market, including the Europe pharmaceutical packaging & labeling market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present pharmaceutical packaging & labeling market and its market dynamics for 2023-2028 in Europe.

CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals

Retrieved on: 
Tuesday, October 24, 2023

CEL-SCI Corporation (NYSE American: CVM) today released a video presentation in which the Company’s CEO, Geert Kersten, shares the most recent data presented at the European Society for Medical Oncology (ESMO) Congress and the data’s impact on propelling the Company’s immunotherapy drug Multikine* (Leukocyte Interleukin, Injection) toward regulatory approval for the treatment of newly diagnosed, advanced squamous cell carcinoma of the head and neck (SCCHN).

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today released a video presentation in which the Company’s CEO, Geert Kersten, shares the most recent data presented at the European Society for Medical Oncology (ESMO) Congress and the data’s impact on propelling the Company’s immunotherapy drug Multikine* (Leukocyte Interleukin, Injection) toward regulatory approval for the treatment of newly diagnosed, advanced squamous cell carcinoma of the head and neck (SCCHN).
  • Mr. Kersten carefully explains how it is that patients in the target group who were treated with Multikine had a 5-year survival rate of 73% as compared to only 45% for those who did not receive Multikine, cutting the risk of death by half.
  • He goes on to present CEL-SCI’s regulatory submissions plan and timelines based on these compelling findings for a patient population that has not had a new treatment approved in in the U.S. in many decades.
  • Summary of Multikine Results in the Target Population:
    Target population of an estimated 145,000 patients (global, annual) who present with:
    Physicians routinely assess these features at baseline; no extra tests needed
    These features make it easy to write a label for the approval of Multikine, which is essential for drug approval

Public advisory - Unauthorized health products seized from online retailer "UU Zone" may pose serious health risks

Retrieved on: 
Wednesday, October 25, 2023

Health Canada is warning consumers about unauthorized health products it seized from UU Zone, an online retailer, based in Markham, ON.

Key Points: 
  • Health Canada is warning consumers about unauthorized health products it seized from UU Zone, an online retailer, based in Markham, ON.
  • The products are labelled to contain medicinal drugs and may pose serious health risks.
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • Read product labels to verify that health products have been authorized for sale by Health Canada.

Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease

Retrieved on: 
Wednesday, October 18, 2023

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718 for the treatment of Huntington’s disease (HD).

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718 for the treatment of Huntington’s disease (HD).
  • Cognitive impairment is one of the most underrecognized aspects of this disease,” said Laura Gault, M.D., Ph.D., Chief Medical Officer, Sage Therapeutics.
  • The approval of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval.
  • SAGE-718 previously received Fast Track Designation from the FDA for HD, and orphan drug designation for HD by the European Medicines Agency.

Cabinet Health Introduces “Cabinet Health Rx” the World’s First Plastic-free and Refillable Prescription Solution

Retrieved on: 
Wednesday, October 18, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231018233404/en/
    Cabinet Health Rx Bottle (Photo: Business Wire)
    Cabinet Health Rx enters the market with more than 150 of the most commonly used prescription drugs.
  • Each new patient onboards with a personally designed refillable glass bottle and is partnered with a dedicated Cabinet Care professional.
  • Once a Cabinet patient, refills and renewals are handled by the Cabinet Health Rx care team.
  • Cabinet Health is a certified B-Corp that prioritizes minimizing carbon footprint, water waste, and material waste in their offerings and practices.

Innocan Pharma reports a groundbreaking discovery regarding its LPD platform and global CBD research

Retrieved on: 
Monday, October 23, 2023

Research over the past several months has identified animals that metabolize cannabidiol (CBD), administered as a liposomal CBD injection, in a manner similar to humans.

Key Points: 
  • Research over the past several months has identified animals that metabolize cannabidiol (CBD), administered as a liposomal CBD injection, in a manner similar to humans.
  • This groundbreaking discovery, is not unique to our LPT-CBD and can be implemented on these animals using other Cannabidiol (CBD) delivery methods", said Iris Bincovich, CEO of Innocan Pharma.
  • This practical application of our liposomal CBD formulation highlights its potential to revolutionize healthcare for animals as well as humans.
  • Our groundbreaking data identified animals that have the potential for studying pharmacokinetics, pharmacodynamics, and safety of liposomal-CBD formulation.

Opioid and Stimulant Overdose Reporting Program to Expand Under Increased Federal Funding

Retrieved on: 
Tuesday, October 17, 2023

This project was expanded with a contract award in September 2023, titled the Drug Overdose Toxico-Surveillance (DOTS) Reporting Program , which was created with the aim to provide accurate data on the evolving role of polysubstance use in non-fatal opioid- and stimulant-involved drug overdoses.

Key Points: 
  • This project was expanded with a contract award in September 2023, titled the Drug Overdose Toxico-Surveillance (DOTS) Reporting Program , which was created with the aim to provide accurate data on the evolving role of polysubstance use in non-fatal opioid- and stimulant-involved drug overdoses.
  • Comprehensive laboratory testing of the samples is conducted by the Center for Forensic Science Research and Education (CFSRE) .
  • CSFRE testing methods facilitate detection of over one thousand analytes (prescription drugs and illicit substances, including novel emerging substances).
  • Led by medical toxicology physicians and registry experts, our projects involve case registry design and maintenance.

Curative Launches Innovative Health Insurance Plan in Florida, Eliminating Copays and Deductibles*

Retrieved on: 
Tuesday, October 17, 2023

The findings point to a looming health crisis and the failure of traditional health plans to provide adequate access to care.

Key Points: 
  • The findings point to a looming health crisis and the failure of traditional health plans to provide adequate access to care.
  • Curative’s unique $0 copay, $0 deductible plan* is a progressive solution to traditional health plans and gives members affordable access to high-quality health care.
  • “As we have seen across Texas, Curative’s health plan is constructed to fix the shortcomings of traditional health insurance by removing the financial barriers to care by offering $0 copays and $0 deductibles.
  • To learn more about Curative's revolutionary health insurance plan and how it can benefit employers and employees alike, visit https://curative.com/ .

Gorilla Lifestyle introduces groundbreaking hemp-based energy shots and gummies, revolutionizing the legal hemp industry

Retrieved on: 
Tuesday, October 17, 2023

MIAMI BEACH, Fla., Oct. 17, 2023 /PRNewswire/ -- Introducing  Gorilla Energy Shots and Gorilla Gummies, the debut products from Gorilla Lifestyle. A new player in the industrial hemp market, Gorilla Lifestyle is launching a line of hemp-derived products designed to enhance everyday experiences. With a strong focus on quality ingredients, taste and innovative compound technology, Gorilla Lifestyle is poised for widespread retail availability at affordable prices in almost every U.S. state.

Key Points: 
  • A new player in the industrial hemp market, Gorilla Lifestyle is launching a line of hemp-derived products designed to enhance everyday experiences.
  • Gorilla Lifestyle introduces groundbreaking hemp-based energy shots and gummies, revolutionizing the legal hemp industry
    Carving a niche in an exploding market, Gorilla Lifestyle is appealing to every segment of cannabis consumers, from wellness seekers and club hoppers to baby boomers who enjoy a safe, therapeutic buzz, but are wary of potential side effects associated with smoking weed, prescription drugs and alcohol.
  • "We are excited to launch our Gorilla Lifestyle collection and share our passion with a wide community," said Karan Riana, CEO and Co-Founder of Gorilla Lifestyle.
  • Gorilla Lifestyle works with hemp, which is legal under the Agricultural Improvement Act , otherwise known as the 2018 Farm Bill.